Thus, future work will focus on expansion of the NT-1044 treatment studies into additional patient-derived xenograft mouse models of endometrial cancer of varying genomic backgrounds to assess for potential biomarkers of NT-1044 response that may also align with obesity status, in particular mutations that affect the AMPK/mTOR pathway, a pathway well-known to be altered in both obesity and endometrial cancer. This evidence concerns the gene MTOR and endometrial cancer.